Past voting member and Chair of US FDA Oncology Drug Advisory Committee (ODAC) Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research Internationally renowned authority on the regulatory approval of drugs for hematologic malignancies and clinical trials
30+ years as a pharmacokineticist in industry where she specialized in population pharmacokinetic / pharmacodynamic modeling Extensive experience in filing regulatory applications to FDA Has been involved in countless applications for hematopoietic agents, monoclonal antibodies and anti-cancer therapies
Internationally recognized authority on early phase clinical trial design, pharmacokinetics, Project Optimus, and regulatory strategy Presently VP for Clinical Development at Pathos Previous Medical Lead for CRISPER technologies, Intellia Therapeutics, Inc. Physician Scientist, ASCO Cancer Research Committee
President and Chief Medical Officer of Sarah Cannon Research Institute Executive Director, Drug Development for the research institute. International authority in drug development, clinical trials and regulatory process President Elect of ASCO (2019-2020)